Viatris Inc
NASDAQ:VTRS
Viatris Inc
Total Current Liabilities
Viatris Inc
Total Current Liabilities Peer Comparison
Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Viatris Inc
NASDAQ:VTRS
|
Total Current Liabilities
$7.8B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Current Liabilities
$48.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Current Liabilities
$25.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
24%
|
CAGR 10-Years
13%
|
|
Pfizer Inc
NYSE:PFE
|
Total Current Liabilities
$40.5B
|
CAGR 3-Years
15%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
Merck & Co Inc
NYSE:MRK
|
Total Current Liabilities
$25.1B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
1%
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Current Liabilities
$18.6B
|
CAGR 3-Years
17%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
See Also
What is Viatris Inc's Total Current Liabilities?
Total Current Liabilities
7.8B
USD
Based on the financial report for Mar 31, 2024, Viatris Inc's Total Current Liabilities amounts to 7.8B USD.
What is Viatris Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
11%
Over the last year, the Total Current Liabilities growth was 27%. The average annual Total Current Liabilities growth rates for Viatris Inc have been -8% over the past three years , 13% over the past five years , and 11% over the past ten years .